Risk and safety to stop antiplatelet (aspirin)to perform an initial diagnostic endoscopy
Phase 2
- Conditions
- Coronary artery disease patients not to be stopped aspirin to perform an initial diagnostic endoscopy.
- Registration Number
- JPRN-UMIN000004813
- Lead Sponsor
- Graduate School of Medical Sciences, Kumamoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Malignancy, Zollinger-Ellison syndrome, pregnancy, a history of esophago-gastric surgery, continue bleeding from the GI tract, can not use the cilostazol, and can not take informed consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method bleeding rate to be performed the endoscopic procedures(biopsy) and adverse ischemic event rate to stop aspirin.
- Secondary Outcome Measures
Name Time Method Efficacy and safety to Cilostazol